Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2014 / Cilt: 24 - Sayı: 3

Myelom Hastalarında Tanı Anında Demir Yüklenme Sıklığı ve Bunun Klinik Önemi

Iron Overload Pattern in Multiple Myeloma at Diagnosis its Important Clinical Associations

Pages
185–189
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In conclusion, IO is also not infrequent MM at diagnosis and it has some clinical associations.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:As a plasmaproliferative disorder, multiple myeloma (MM) is not expected to cause IO and actually there are no reports on this condition in MM.
📊
Key Findings & Data:Iron overload pattern (IOP) was described as increased transferring saturation (> 45%) in the presence of normal to increased serum iron and ferritin levels.
💡
Conclusion & Impact:In conclusion, IO is also not infrequent MM at diagnosis and it has some clinical associations.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

As a plasmaproliferative disorder, multiple myeloma (MM) is not expected to cause IO and actually there are no reports on this condition in MM. In this retrospective study, we evaluated serum iron test results in MM patients at diagnosis in order to find the frequency of IO. Iron overload pattern (IOP) was described as increased transferring saturation (> 45%) in the presence of normal to increased serum iron and ferritin levels. Among 90 newly diagnosed MM patients (54 male, 36 female, and the median age: 61 years, range: 31-86) IOP was found in 17 cases (17/90, 19%). There was a close association between lambda light chain type paraproteinemia and IOP (13/17 in IOP cohort vs 26/73 lambda paraproteinemia, p= 0.003). Half of the MM patients (7/14) with free lambda light chain paraproteinemia had IOP. The main reason of the elevated TS was increased serum iron level in IOP patients, 144 (±71) vs 57 (±24) pg/ml (p< .001). Four out of 17 IOP patients had extramedullary involvement and this was significantly more frequent than the other patients. Although high International Staging System risk disease (stage 2 or 3) was more frequent in IOP patients (15/15 vs 51/68, p= 0.03), we could not observe any difference regarding treatment response, and survival between these cases and others. In conclusion, IO is also not infrequent MM at diagnosis and it has some clinical associations.

Özet

Plazma proliferatif bir hastalık olan multiple myelomun demir yüklenmesine neden olması beklenmediği gibi bu durumla ilgili herhangi bir bilgi bulunmamaktadır. Bu retrospektif çalışmada, multiple myelom hastalarını demir yüklenme sıklığını öğrenmek için tanı anındaki serum demir testleri ile incelendi. Demir yüklenme paterni, normal- yüksek serum demir ve ferritin düzeyi varlığında, transferin saturasyonunun >%45 olması olarak kabul edildi. Yeni tanı almış 90 MM hastasından (54 erkek, 36 kadın ve ortalama yaş 61, yaş aralığı 31-86 yıl) 17’sinde (17/90,%19 )demir yüklenme paterni saptandı. Lambda hafif zincir tip paraproteinemi ile demir yüklenmesi arasında yakın ilişki vardı (13/17 demir yüklenme paterni ve 26/73 lambda proteinemi, p= 0.003) .Serbest lambda hafif zincir tip MM hastalarının yarısında (7/14) demir yüklenme paterni vardı. Artmış transferin saturasyonu azalmiş total demir bağlama kapasitesinden kaynaklanmıyordu. Total demir bağlama kapasitesi değeri, demir yüklenmesi olan ve olmayan gruplarda benzerdi. Artmış TS’ unun asıl nedeni serum demir değerinin artmasıydı 144 (±71) vs 57 (±24) pg/ml (p< 0.001). Demir yüklenmesi olan 17 hastanın 4’ ünde ekstramedüller tutulum vardı ve bu oran diğer hastalardan anlamlı olarak daha fazlaydı. Yüksek ISS(stage 2 ya da 3) skoruna sahip hastalar demir yüklenmesi olan grupta daha sık olmakla birlikte (15/15 vs 51/68, p= 0.03) , bu grup ile diğerleri arasında tedavi yanıtı ve yaşam süreleri açısından herhangi bir fark gözlemlenmedi . Özetle; demir yüklenmesi yeni tanı MM hastalarında sıkça görülür ve bazı klinik sonuçları vardır.

🔖

Cite This Article

ELİAÇIK, E., KORUCU, B., BALABAN, S., IŞIK, A., HAZNEDAROĞLU, İ. C., GÖKER, H., AKSU, S., SAYINALP, N., BÜYÜKAŞIK, Y. (2014). Myelom Hastalarında Tanı Anında Demir Yüklenme Sıklığı ve Bunun Klinik Önemi. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 24 - Sayı: 3, 185–189. https://ajindex.com/articles/322913

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Savas MC, Benekli M, Haznedaroglu IC, Dundar SV. Bulky plasmacytoma of the skull with intracranial involvement. Am J Hematol 54: 173, 1997.
  2. Serefhanoglu S, Haznedaroglu IC, Goker H, Buyukasik Y, Ozcebe OI. Multiple bulky cutaneous plasmacytomas with CNS relapse without bone marrow involvement during the course of a lambda light chain myeloma. Onkologie 32: 662- 664, 2009.
  3. Serefhanoglu S, Sayinalp N, Haznedaroglu IC, et al. Extramedullary plasmacytomas of the thyroid and pericardium as initial presentation of multiple myeloma. Ann Hematol 87: 853-854, 2008.
  4. Song MK, Chung JS, Seol YM, et al. Elevation of serum ferritin is associated with the outcome of patients with newly diagnosed multiple myeloma. Korean J Intern Med 24: 368-373, 2009.
  5. Campanella A, Santambrogio P, Fontana F, et al. Iron increases the susceptibility of multiple myeloma cells to bortezomib. Haematologica 98: 971-979, 2013.
  6. Daniels TR, Ortiz-Sanchez E, Luria-Perez R, et al. An antibody-based multifaceted approach targeting the human transferrin receptor for the treatment of B-cell malignancies. J Immunother 34: 500-508, 2011.
  7. Daniels TR, Neacato II, Rodriguez JA, et al. Disruption of HOX activity leads to cell death that can be enhanced by the interference of iron uptake in malignant B cells. Leukemia 24: 1555-1565, 2010.
  8. Eberhard Y, McDermott SP, Wang X, et al. Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood 114: 3064-1073, 2009.
  9. Ouellette D, Alessandri L, Piparia R, et al. Elevated cleavage of human immunoglobulin gamma molecules containing a lambda light chain mediated by iron and histidine. Anal Biochem 389: 107-117, 2009.
  10. Rodriguez JA, Luria-Perez R, Lopez-Valdes HE, et al. Lethal iron deprivation induced by non-neutralizing antibodies targeting transferrin receptor 1 in malignant B cells. Leuk Lymphoma 52: 2169-2178, 2011.
  11. Suzuki E, Daniels TR, Helguera G, et al. Inhibition of NF-kappaB and Akt pathways by an antibody-avidin fusion protein sensitizes malignant B-cells to cisplatin-induced apoptosis. Int J oncol 36: 1299-3107, 2010. Piperno A. Classification and diagnosis of iron overload. Haematologica 83: 447-455, 1998.
  12. Buyukasik NS, Nadir I, Akin FE, et al. Serum iron parameters in cirrhosis and chronic hepatitis: detailed description. Turk J Gastroenterol 22: 606-611, 2011. Wallach J (Ed). Interpretation of diagnostic tests. 8th edition. Philadelphia, Lippincott Williams and Wilkins, 2007: 270-271.